Efficacy of FOLFOX chemotherapy combined with anti-angiogenic targeted drugs (bevacizumab/surufatinib) in neuroendocrine tumours after progression following multiple lines of therapy: A retrospective study

#4293

Introduction: The FOLFOX regimen (combining 5-fluorouracil, leucovorin, and oxaliplatin) has been widely used for treating various cancers, including NETs. However, the effectiveness of combining FOLFOX with antiangiogenic agents in NETs after progression on multiple therapies remains unclear.

Aim(s): The study aims to explore the efficacy of the FOLFOX combined with antiangiogenic targeted drugs (Bevacizumab/Surufatinib) in the treatment of neuroendocrine tumours (NETs) after progression following multiple lines of therapy.

Materials and methods: A retrospective analysis was conducted on clinical data of patients treated at the Neuroendocrine Tumor Center of Fudan University Cancer Hospital from July 2021 to October 2024. These patients, who had progressed after multiple lines of treatment, received FOLFOX, FOLFOX+Bevacizumab, or FOLFOX+Surufatinib therapies.

Conference:

Presenting Author: Liang Y

Authors: Liang Y, Jia X, Sun Z, Chen J,

Keywords: FOLFOX, chemotherapy, antiangiogenic agents, G3,